tirzepatide discontinuation discontinuation of tirzepatide was associated with substantial weight regain - Tirzepatidewithdrawal symptoms People tend to regain weight rapidly after stopping weight-loss drugs Understanding Tirzepatide Discontinuation: What Happens When You Stop?

Discontinuationof glucagon-like peptide-1 receptor agonists The emergence of medications like tirzepatide has offered a significant advancement in the management of obesity and type 2 diabetes. These drugs, which act as dual GLP-1 RA and GIP/GLP-1 RA agonists, have demonstrated remarkable efficacy in promoting weight loss and improving metabolic control.2025年9月9日—Among patients who stopped takingtirzepatide, 31.0% doubled their weight loss after two years, 15.2% lost some additional weight, and 9.0% ... However, a crucial question arises for many individuals: what are the implications of tirzepatide discontinuation? Emerging research and clinical observations suggest a complex picture, with significant implications for weight management and cardiometabolic health.Metabolic rebound after GLP-1 receptor agonist ...

Studies, such as those discussed in the SURPASS-1 monotherapy trial, have investigated the impact of ceasing tirzepatide. The primary finding is that withdrawing tirzepatide led to substantial regain of lost weight. This phenomenon, often referred to as "weight rebound" or metabolic rebound, indicates that the benefits of tirzepatide are largely dependent on its continued useChanges in weight and glycemic control following obesity .... For instance, the SURMOUNT-4 trial specifically highlighted that discontinuation of tirzepatide was associated with substantial weight regainSemaglutide and Tirzepatide Discontinuation Rates High. This underscores the importance of tirzepatide in maintaining the weight loss achieved during treatment.

The rapid return of lost weight after discontinuing these medications is a consistent finding across various studies. As noted, people tend to regain weight rapidly after stopping weight-loss drugs, often at a faster rate than after ending behavioral weight loss programs alone. This highlights that tirzepatide is not a standalone cure but a powerful tool that requires ongoing adherence. For individuals who have experienced significant weight loss, the prospect of weight gain after GLP-1 discontinuation is a critical consideration.

Furthermore, the effects of tirzepatide discontinuation extend beyond weight.Weight Reduction Following Obesity Treatment Varies by ... Cardiometabolic risk factors, which often improve with tirzepatide treatment, can also be compromised.作者：CC Tzang·2025·被引用次数：3—∙ et al.Discontinuation of tirzepatide and semaglutide prior to gastric sleeve surgery: clinical considerations and guidelines. Obes Surg. 2025; 35(5):1579 ... Research indicates that tirzepatide discontinuation reduces cardiometabolic improvements, suggesting that the drug plays a role in long-term cardiovascular and metabolic health2025年7月10日—Key takeaways: · Adults who discontinued their obesity medication after less than 1 year lost 3.6% of their body weight. · Continuing obesity .... Continued treatment, as demonstrated in trials like SURMOUNT-4, shows that continuing treatment with tirzepatide is superior to discontinued therapy for the maintenance of body weight reduction.2025年9月9日—Among patients who stopped takingtirzepatide, 31.0% doubled their weight loss after two years, 15.2% lost some additional weight, and 9.0% ... This means that for many, continuing treatment leads to an additional shedding of pounds and sustained health benefits.

Several factors can contribute to tirzepatide discontinuation. While adverse events (AEs) can be a cause, with studies showing discontinuation of tirzepatide is common in randomized controlled trials due to side effects, other practical reasons are also significantClinical and Neurobehavioral Changes With Weight Loss .... Research by H Gasoyan in 2025 identified that a substantial percentage of patients discontinue medication due to cost or insurance-related issues作者：H Gasoyan·2025·被引用次数：6—This study aimed to characterize the reasons for treatmentdiscontinuationwith injectable semaglutide ortirzepatidefor obesity in regular .... This points to the accessibility challenges that can impede long-term treatment adherenceThe promise of tirzepatide: A narrative review of metabolic benefits. Data also suggests a high discontinuation rate of both semaglutide and tirzepatide in real-world settings, sometimes reaching up to 50% at one year.2025年5月15日—Discontinuationoftirzepatidemay compromise long-term cardiometabolic risk factor control. After 176 weeks oftirzepatidetreatment among ...

For some individuals, tirzepatide might be discontinued for specific surgical procedures. For example, guidelines exist for discontinuation of tirzepatide and semaglutide prior to gastric sleeve surgery. Understanding the timing and definition of discontinuation is also crucialDiscontinuation and Reinitiation of GLP-1 Receptor Agonists. In clinical contexts, discontinuation can be defined by a patient being 60 days or more without a medication fill, or it can refer to an early cessation of therapy. Indeed, different patterns of discontinuation exist, with some studies observing that 16.4% discontinued early from tirzepatide treatment.

There is also interest in the concept of a brief discontinuation of the drug for roughly 3-4 weeks, followed by reinitiation. This experimental approach aims to understand the drug's impact on various physiological and behavioral aspects, such as hunger, mood, and sleep. However, the general consensus remains that without ongoing tirzepatide therapy, the benefits achieved are likely to diminishWeight loss maintenance after tirzepatide cessation in people ....

In summary, while tirzepatide offers substantial benefits for weight loss and metabolic health, tirzepatide discontinuation typically results in significant weight regain and a reversal of cardiometabolic improvements. The decision to stop this medication should be made in close consultation with a healthcare provider, weighing the potential risks of weight rebound against any reasons for discontinuation.作者：ABM Kamrul-Hasan·2025·被引用次数：4—Despite therapeutic benefits,discontinuation of tirzepatide is common in randomized controlled trials(RCTs) due to adverse events (AEs) and other causes. For many, sustained use is key to maximizing and maintaining the therapeutic advantages of tirzepatide.Does discontinuing tirzepatide lead to weight regain?